BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Acucela Inc. Reaches 50% Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial


8/28/2013 10:48:52 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight-threatening eye diseases, today announced that it has achieved 50% subject enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat hydrochloride in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). The Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (the SEATTLE) study is a multicenter, randomized, double-masked, dose-ranging study initiated earlier this year (ClinicalTrials.gov identifier: NCT01802866). A total of approximately 440 patients with GA associated with dry AMD are expected to be enrolled in the study across 56 sites, primarily in the United States. Emixustat hydrochloride is being studied to determine whether it slows the progression of GA lesions in these patients.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES